Drugs / Tumor Lysate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01803152 | Jan 2014 → Sep 2019 | bone sarcoma, soft tissue sarcoma | Macarena De La Fuente, MD | Completed | No outcome recorded |
| Phase 1 | NCT01902771 | Sep 2013 → Oct 2016 | brain cancer, glioblastoma | Edward Ziga | Terminated | No outcome recorded |
| Phase 1 | NCT01808820 | Aug 2013 → Nov 2018 | anaplastic astrocytoma, glioblastoma | Macarena De La Fuente, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Lysate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01808820 ↗ |
| Known as | Lysate of Tumor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01803152 ↗ |
| Route | Other | “administered via intradermal injection” NCT01902771 ↗ |